It said that the PTAB’s decision contradicted the US Supreme Court, which has repeatedly reaffirmed tribal immunity as settled law. The brief argued that the board erred in its decision that it could proceed with the IPRs in the tribe’s absence because Allergan is the “effective patent owner” of the …
